Multiple Sclerosis Drugs Market is expected to grow at a CAGR of 6.3% during the forecast period. Multiple Sclerosis Drugs Market is expected to reach US$ 47.45 Bn. by 2029. Multiple sclerosis is a long lasting disease that can affect the spinal cord, brain, and the optic nerves in eyes. It can cause problems such as muscle control, vision, balance and other basic body functions. Multiple sclerosis also referred as disseminated sclerosis. At present, primary progressive multiple sclerosis market is facing lucrative growth because of the rising incidences of multiple sclerosis globally a patient awareness may promote the future growth of this market.To know about the Research Methodology:-Request Free Sample Report The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Multiple Sclerosis Drugs Market Drivers and Restrains
Currently, numerous types of relapsing multiple sclerosis are gradually affecting the large number of populations globally, such as secondary-progressive multiple sclerosis (SPMS), relapsing remitting multiple sclerosis and progressive relapsing multiple sclerosis. According to multiple sclerosis web portal by United States and Health Union more than xx Mn people are affected by multiple sclerosis globally. Among the all different types of multiple sclerosis, xx % patients suffer from primary progressive multiple sclerosis. It is difficult to diagnose as well as treat these patients. Therefore, elevated demand for the advanced therapeutic treatment will fuel the growth of primary progressive multiple sclerosis (PPMS) market. The drugs used to treat multiple sclerosis are Interferon Beta (Avonex, Betaseron, Extavia, Plegridy, Rebif), Glatiramer Acetate (Copaxone, Glatopa), Fingolimod (Gilenya), Teriflunomide (Aubagio), Dimethyl Fumarate (Tecfidera) and others. The multiple sclerosis drug companies are increasing their offerings for interferon-β drugs, attributing to their efficiency for T cell leukemia associated with myelopathy, glioma, and tropical spastic par paresis. The hopeful results of multiple sclerosis drugs have also been addressed in fingolimod in intra cerebral hemorrhage and acute ischemic stroke. Therefore, ongoing research and development in the multiple sclerosis drugs market will lead to the arrival of innovative drugs for multiple sclerosis. Similarly, advances in multiple sclerosis drugs have led to effective medications for the relapsing and progressive forms of multiple sclerosis. In March 2022, Norvatis AG is Swiss multinational pharmaceutical company and a leading player operating in the multiple sclerosis drugs market announced the launch of the FDA approved multiple sclerosis drug such as Mayzent (siponimod), for the treatment of various multiple sclerosis conditions. Manufacturers in the Multiple Sclerosis Drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.Multiple Sclerosis Drugs Market Segmentation Analysis
The multiple sclerosis drugs market is segmented into four types such as drug class, route of administration, distribution channel and region. On the basis of route of administration, market is subdivided into oral and injection. The injection segment accounted for maximum profit in 2022, because of the active government recommendations and global market approvals. On the basis of drug class market is categorized into immunomodulators, immunosuppressants, interferons and others. In terms of distribution channels covered under the report are retail pharmacy, hospital pharmacy, and online stores. The immunomodulators used to diagnose Multiple Sclerosis such as glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate (BG-12) and others. Biogen has occurred as a leading player in the multiple sclerosis drugs market because of the higher sales of Tecdera in 2022 and strategic partnership for increased distribution of drugs. Based on region, it is studied across Asia Pacific, North America, Europe, Latin America and Middle East Africa.Multiple Sclerosis Drugs Market Regional Analysis
On the basis of region Multiple Sclerosis Drugs market divided into five region such as Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among all the regions, North America had hold the largest market share in 2022 and is projected to lead the market during the forecast period. Because of high incidence rates of multiple sclerosis and rising demands for therapeutic medications for the effective treatment of primary progressive multiple sclerosis in these regions. In recent studies of multiple sclerosis portal xx % people are affected by multiple sclerosis in Europe and xx % affected population is present in the United States. This can be credited to the higher sales of multiple sclerosis drugs in countries such as the United State and Canada. Furthermore, Asia Pacific is expected to expand at a comparatively high CAGR during the forecast period. The multiple sclerosis drugs market in Asia Pacific is driven by a large pool of patients with multiple sclerosis disease in China and Japan, launch and approval of new products, and growth in investments by leading players in the region in therapeutic drugs for multiple sclerosis disease. Therefore, the Asia Pacific is expected to be the second largest market over the forecast period and nearly follow by North America in terms of profits. The objective of the report is to present comprehensive analysis of Multiple Sclerosis Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Multiple Sclerosis Drugs Market dynamics, structure by analyzing the market segments, and project the Multiple Sclerosis Drugs Market size. Clear representation of competitive analysis of key players by Multiple Sclerosis Drugs Type, price, financial position, product portfolio, growth strategies, and regional presence in the Multiple Sclerosis Drugs Market make the report investor’s guide.Scope of the Multiple Sclerosis Drugs Market: Inquire before buying
Global Multiple Sclerosis Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 30.93 Bn. Forecast Period 2023 to 2029 CAGR: 6.3% Market Size in 2029: US $ 47.45 Bn. Segments Covered: by Drug Class Immunomodulators Immunosuppressants Interferons Others by Route of Administration Oral Injection by Distribution Channel Hospital Pharmacies Retail Online Sales Multiple Sclerosis Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Multiple Sclerosis Drugs Market, Key Players are
1. Norvatis AG 2. Allergan Plc. 3. Hoffmann-La Roche Ltd. 4. Astellas 5. Biocodex S A 6. Consumer Healthcare Inc. 7. Dainippon Sumitomo 8. ECR Pharmaceuticals 9. Eisai Co. 10. Flynn Pharma 11. Johnson and Johnson 12. Meda Consumer Healthcare Inc. 13. Merck and Co. Inc. 14. Neurim 15. Pernix Therapeutics 16. Pfizer Inc 17. Purdue Pharma L.P. 18. Sanofi Pasteur 19. SkyePharma 20. Takeda Pharmaceutical Company 21. Genzyme Corporation 22. Teva Pharmaceuticals USA, Inc. 23. Mallinckrodt 24. Hikma Pharmaceuticals PLC 25. Par PharmaceuticalFrequently Asked Questions:
1. Which region has the largest share in Global Multiple Sclerosis Drugs Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Multiple Sclerosis Drugs Market? Ans: The Global Multiple Sclerosis Drugs Market is growing at a CAGR of 6.3% during forecasting period 2023-2029. 3. What is scope of the Global Multiple Sclerosis Drugs market report? Ans: Global Multiple Sclerosis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Multiple Sclerosis Drugs market? Ans: The important key players in the Global Multiple Sclerosis Drugs Market are – Norvatis AG, Allergan Plc., Hoffmann-La Roche Ltd., Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson and Johnson, Meda Consumer Healthcare Inc., Merck and Co. Inc., Neurim, Pernix Therapeutics, Pfizer Inc, Purdue Pharma L.P., Sanofi Pasteur, SkyePharma, Takeda Pharmaceutical Company, Genzyme Corporation, Teva Pharmaceuticals USA, Inc., Mallinckrodt, Hikma Pharmaceuticals PLC, and Par Pharmaceutical 5. What is the study period of this market? Ans: The Global Multiple Sclerosis Drugs Market is studied from 2022 to 2029.
1. Multiple Sclerosis Drugs Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Multiple Sclerosis Drugs Market: Dynamics 2.1. Multiple Sclerosis Drugs Market Trends by Region 2.1.1. North America Multiple Sclerosis Drugs Market Trends 2.1.2. Europe Multiple Sclerosis Drugs Market Trends 2.1.3. Asia Pacific Multiple Sclerosis Drugs Market Trends 2.1.4. Middle East and Africa Multiple Sclerosis Drugs Market Trends 2.1.5. South America Multiple Sclerosis Drugs Market Trends 2.2. Multiple Sclerosis Drugs Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Multiple Sclerosis Drugs Market Drivers 2.2.1.2. North America Multiple Sclerosis Drugs Market Restraints 2.2.1.3. North America Multiple Sclerosis Drugs Market Opportunities 2.2.1.4. North America Multiple Sclerosis Drugs Market Challenges 2.2.2. Europe 2.2.2.1. Europe Multiple Sclerosis Drugs Market Drivers 2.2.2.2. Europe Multiple Sclerosis Drugs Market Restraints 2.2.2.3. Europe Multiple Sclerosis Drugs Market Opportunities 2.2.2.4. Europe Multiple Sclerosis Drugs Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Multiple Sclerosis Drugs Market Drivers 2.2.3.2. Asia Pacific Multiple Sclerosis Drugs Market Restraints 2.2.3.3. Asia Pacific Multiple Sclerosis Drugs Market Opportunities 2.2.3.4. Asia Pacific Multiple Sclerosis Drugs Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Multiple Sclerosis Drugs Market Drivers 2.2.4.2. Middle East and Africa Multiple Sclerosis Drugs Market Restraints 2.2.4.3. Middle East and Africa Multiple Sclerosis Drugs Market Opportunities 2.2.4.4. Middle East and Africa Multiple Sclerosis Drugs Market Challenges 2.2.5. South America 2.2.5.1. South America Multiple Sclerosis Drugs Market Drivers 2.2.5.2. South America Multiple Sclerosis Drugs Market Restraints 2.2.5.3. South America Multiple Sclerosis Drugs Market Opportunities 2.2.5.4. South America Multiple Sclerosis Drugs Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Multiple Sclerosis Drugs Industry 2.8. Analysis of Government Schemes and Initiatives For Multiple Sclerosis Drugs Industry 2.9. Multiple Sclerosis Drugs Market Trade Analysis 2.10. The Global Pandemic Impact on Multiple Sclerosis Drugs Market 3. Multiple Sclerosis Drugs Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 3.1.1. Immunomodulators 3.1.2. Immunosuppressants 3.1.3. Interferons 3.1.4. Others 3.2. Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 3.2.1. Oral 3.2.2. Injection 3.3. Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 3.3.1. Hospital Pharmacies 3.3.2. Retail 3.3.3. Online Sales 3.4. Multiple Sclerosis Drugs Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Multiple Sclerosis Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.1.1. Immunomodulators 4.1.2. Immunosuppressants 4.1.3. Interferons 4.1.4. Others 4.2. North America Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 4.2.1. Oral 4.2.2. Injection 4.3. North America Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 4.3.1. Hospital Pharmacies 4.3.2. Retail 4.3.3. Online Sales 4.4. North America Multiple Sclerosis Drugs Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.4.1.1.1. Immunomodulators 4.4.1.1.2. Immunosuppressants 4.4.1.1.3. Interferons 4.4.1.1.4. Others 4.4.1.2. United States Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 4.4.1.2.1. Oral 4.4.1.2.2. Injection 4.4.1.3. United States Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 4.4.1.3.1. Hospital Pharmacies 4.4.1.3.2. Retail 4.4.1.3.3. Online Sales 4.4.2. Canada 4.4.2.1. Canada Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.4.2.1.1. Immunomodulators 4.4.2.1.2. Immunosuppressants 4.4.2.1.3. Interferons 4.4.2.1.4. Others 4.4.2.2. Canada Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 4.4.2.2.1. Oral 4.4.2.2.2. Injection 4.4.2.3. Canada Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 4.4.2.3.1. Hospital Pharmacies 4.4.2.3.2. Retail 4.4.2.3.3. Online Sales 4.4.3. Mexico 4.4.3.1. Mexico Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 4.4.3.1.1. Immunomodulators 4.4.3.1.2. Immunosuppressants 4.4.3.1.3. Interferons 4.4.3.1.4. Others 4.4.3.2. Mexico Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 4.4.3.2.1. Oral 4.4.3.2.2. Injection 4.4.3.3. Mexico Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 4.4.3.3.1. Hospital Pharmacies 4.4.3.3.2. Retail 4.4.3.3.3. Online Sales 5. Europe Multiple Sclerosis Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.2. Europe Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.3. Europe Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4. Europe Multiple Sclerosis Drugs Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.1.2. United Kingdom Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.1.3. United Kingdom Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.2. France 5.4.2.1. France Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.2.2. France Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.2.3. France Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.3. Germany 5.4.3.1. Germany Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.3.2. Germany Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.3.3. Germany Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.4. Italy 5.4.4.1. Italy Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.4.2. Italy Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.4.3. Italy Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.5. Spain 5.4.5.1. Spain Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.5.2. Spain Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.5.3. Spain Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.6.2. Sweden Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.6.3. Sweden Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.7. Austria 5.4.7.1. Austria Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.7.2. Austria Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.7.3. Austria Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 5.4.8.2. Rest of Europe Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 5.4.8.3. Rest of Europe Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6. Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.2. Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.3. Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4. Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.1.2. China Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.1.3. China Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.2.2. S Korea Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.2.3. S Korea Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.3. Japan 6.4.3.1. Japan Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.3.2. Japan Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.3.3. Japan Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.4. India 6.4.4.1. India Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.4.2. India Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.4.3. India Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.5. Australia 6.4.5.1. Australia Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.5.2. Australia Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.5.3. Australia Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.6.2. Indonesia Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.6.3. Indonesia Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.7.2. Malaysia Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.7.3. Malaysia Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.8.2. Vietnam Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.8.3. Vietnam Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.9.2. Taiwan Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.9.3. Taiwan Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 6.4.10.2. Rest of Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 6.4.10.3. Rest of Asia Pacific Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 7. Middle East and Africa Multiple Sclerosis Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.2. Middle East and Africa Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 7.3. Middle East and Africa Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 7.4. Middle East and Africa Multiple Sclerosis Drugs Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.4.1.2. South Africa Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 7.4.1.3. South Africa Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 7.4.2. GCC 7.4.2.1. GCC Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.4.2.2. GCC Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 7.4.2.3. GCC Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.4.3.2. Nigeria Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 7.4.3.3. Nigeria Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 7.4.4.2. Rest of ME&A Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 7.4.4.3. Rest of ME&A Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 8. South America Multiple Sclerosis Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.2. South America Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 8.3. South America Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel(2022-2029) 8.4. South America Multiple Sclerosis Drugs Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.4.1.2. Brazil Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 8.4.1.3. Brazil Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.4.2.2. Argentina Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 8.4.2.3. Argentina Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Multiple Sclerosis Drugs Market Size and Forecast, by Drug Class (2022-2029) 8.4.3.2. Rest Of South America Multiple Sclerosis Drugs Market Size and Forecast, by Route of Administration (2022-2029) 8.4.3.3. Rest Of South America Multiple Sclerosis Drugs Market Size and Forecast, by Distribution Channel (2022-2029) 9. Global Multiple Sclerosis Drugs Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Multiple Sclerosis Drugs Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Norvatis AG 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Allergan Plc. 10.3. Hoffmann-La Roche Ltd. 10.4. Astellas 10.5. Biocodex S A 10.6. Consumer Healthcare Inc. 10.7. Dainippon Sumitomo 10.8. ECR Pharmaceuticals 10.9. Eisai Co. 10.10. Flynn Pharma 10.11. Johnson and Johnson 10.12. Meda Consumer Healthcare Inc. 10.13. Merck and Co. Inc. 10.14. Neurim 10.15. Pernix Therapeutics 10.16. Pfizer Inc 10.17. Purdue Pharma L.P. 10.18. Sanofi Pasteur 10.19. SkyePharma 10.20. Takeda Pharmaceutical Company 10.21. Genzyme Corporation 10.22. Teva Pharmaceuticals USA, Inc. 10.23. Mallinckrodt 10.24. Hikma Pharmaceuticals PLC 10.25. Par Pharmaceutical 11. Key Findings 12. Industry Recommendations 13. Multiple Sclerosis Drugs Market: Research Methodology 14. Terms and Glossary